Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Marques-Santos, Cátia M.ORCID iD iconorcid.org/0000-0002-8433-1725
Alternative names
Publications (5 of 5) Show all publications
Marques-Santos, C. M., Friedrich, F., Liu, L., Castoldi, F., Pietrocola, F. & Lanekoff, I. (2023). Global and Spatial Metabolomics of Individual Cells Using a Tapered Pneumatically Assisted nano-DESI Probe. Journal of the American Society for Mass Spectrometry, 34(11), 2518-2524
Open this publication in new window or tab >>Global and Spatial Metabolomics of Individual Cells Using a Tapered Pneumatically Assisted nano-DESI Probe
Show others...
2023 (English)In: Journal of the American Society for Mass Spectrometry, ISSN 1044-0305, E-ISSN 1879-1123, Vol. 34, no 11, p. 2518-2524Article in journal (Refereed) Published
Abstract [en]

Single-cell metabolomics has the potential to reveal unique insights into intracellular mechanisms and biological processes. However, the detection of metabolites from individual cells is challenging due to their versatile chemical properties and concentrations. Here, we demonstrate a tapered probe for pneumatically assisted nanospray desorption electrospray ionization (PA nano-DESI) mass spectrometry that enables both chemical imaging of larger cells and global metabolomics of smaller 15 mu m cells. Additionally, by depositing cells in predefined arrays, we show successful metabolomics from three individual INS-1 cells per minute, which enabled the acquisition of data from 479 individual cells. Several cells were used to optimize analytical conditions, and 93 or 97 cells were used to monitor metabolome alterations in INS-1 cells after exposure to a low or high glucose concentration, respectively. Our analytical approach offers insights into cellular heterogeneity and provides valuable information about cellular processes and responses in individual cells.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2023
National Category
Analytical Chemistry Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-516884 (URN)10.1021/jasms.3c00239 (DOI)001097001800001 ()37830184 (PubMedID)
Funder
Swedish Research Council, 2017-04125EU, European Research Council, 101041224 - X CELLSwedish Research Council, VR MH 2019-02050Novo Nordisk, NNF21OC0070086Novo Nordisk, NNF22OC0078239Swedish Society for Medical Research (SSMF)
Available from: 2023-12-07 Created: 2023-12-07 Last updated: 2024-04-24Bibliographically approved
Arora, A., Becker, M., Marques-Santos, C. M., Oksanen, M., Li, D., Mastropasqua, F., . . . Tammimies, K. (2023). Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Scientific Reports, 13, Article ID 10519.
Open this publication in new window or tab >>Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics
Show others...
2023 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 13, article id 10519Article in journal (Refereed) Published
Abstract [en]

Research continues to identify genetic variation, environmental exposures, and their mixtures underlying different diseases and conditions. There is a need for screening methods to understand the molecular outcomes of such factors. Here, we investigate a highly efficient and multiplexable, fractional factorial experimental design (FFED) to study six environmental factors (lead, valproic acid, bisphenol A, ethanol, fluoxetine hydrochloride and zinc deficiency) and four human induced pluripotent stem cell line derived differentiating human neural progenitors. We showcase the FFED coupled with RNA-sequencing to identify the effects of low-grade exposures to these environmental factors and analyse the results in the context of autism spectrum disorder (ASD). We performed this after 5-day exposures on differentiating human neural progenitors accompanied by a layered analytical approach and detected several convergent and divergent, gene and pathway level responses. We revealed significant upregulation of pathways related to synaptic function and lipid metabolism following lead and fluoxetine exposure, respectively. Moreover, fluoxetine exposure elevated several fatty acids when validated using mass spectrometry-based metabolomics. Our study demonstrates that the FFED can be used for multiplexed transcriptomic analyses to detect relevant pathway-level changes in human neural development caused by low-grade environmental risk factors. Future studies will require multiple cell lines with different genetic backgrounds for characterising the effects of environmental exposures in ASD.

Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Neurosciences
Identifiers
urn:nbn:se:uu:diva-509282 (URN)10.1038/s41598-023-37488-0 (DOI)001022752100018 ()37386098 (PubMedID)
Funder
Knut and Alice Wallenberg FoundationSwedish Research CouncilSwedish Foundation for Strategic ResearchKarolinska InstituteThe Swedish Brain FoundationHarald and Greta Jeansson FoundationÅke Wiberg FoundationThe Swedish Foundation for International Cooperation in Research and Higher Education (STINT)
Available from: 2023-08-23 Created: 2023-08-23 Last updated: 2023-08-23Bibliographically approved
Marques, C., Liu, L., Duncan, K. D. & Lanekoff, I. (2022). A Direct Infusion Probe for Rapid Metabolomics of Low-Volume Samples. Analytical Chemistry, 94(37), 12875-12883
Open this publication in new window or tab >>A Direct Infusion Probe for Rapid Metabolomics of Low-Volume Samples
2022 (English)In: Analytical Chemistry, ISSN 0003-2700, E-ISSN 1520-6882, Vol. 94, no 37, p. 12875-12883Article in journal (Refereed) Published
Abstract [en]

Targeted and nontargeted metabolomics has the potential to evaluate and detect global metabolite changes in biological systems. Direct infusion mass spectrometric analysis enables detection of all ionizable small molecules, thus simultaneously providing information on both metabolites and lipids in chemically complex samples. However, to unravel the heterogeneity of the metabolic status of cells in culture and tissue a low number of cells per sample should be analyzed with high sensitivity, which requires low sample volumes. Here, we present the design and characterization of the direct infusion probe, DIP. The DIP is simple to build and position directly in front of a mass spectrometer for rapid metabolomics of chemically complex biological samples using pneumatically assisted electrospray ionization at 1 mu L/min flow rate. The resulting data is acquired in a square wave profile with minimal carryover between samples that enhances throughput and enables several minutes of uniform MS signal from 5 mu L sample volumes. The DIP was applied to study the intracellular metabolism of insulin secreting INS-1 cells and the results show that exposure to 20 mM glucose for 15 min significantly alters the abundance of several small metabolites, amino acids, and lipids.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2022
National Category
Analytical Chemistry
Identifiers
urn:nbn:se:uu:diva-489972 (URN)10.1021/acs.analchem.2c02918 (DOI)000853252300001 ()36070505 (PubMedID)
Funder
Swedish Foundation for Strategic Research, ITM17-0014Swedish Research Council, 2017-04125
Available from: 2022-12-06 Created: 2022-12-06 Last updated: 2024-04-24Bibliographically approved
Lanekoff, I., Sharma, V. V. & Marques, C. (2022). Single-cell metabolomics: where are we and where are we going?. Current Opinion in Biotechnology, 75, Article ID 102693.
Open this publication in new window or tab >>Single-cell metabolomics: where are we and where are we going?
2022 (English)In: Current Opinion in Biotechnology, ISSN 0958-1669, E-ISSN 1879-0429, Vol. 75, article id 102693Article, review/survey (Refereed) Published
Abstract [en]

Single-cell metabolomics with mass spectrometry enables a large variety of metabolites to be simultaneously detected from individual cells, without any preselection or labelling, to map phenotypes on the single cell level. Although the field is relatively young, it is steadily progressing with an increasing number of active research groups, techniques for cell sampling and ionization, tools for data analysis, and applications to answer important biomedical and environmental questions. In addition, the community shows great creativity in overcoming challenges associated with low sample volumes, a wide range of metabolite species, and large datasets. Here, we briefly discuss publications since 2019 and aim to provide the unfamiliar reader with an insight into the field and the expert reader with an update on the current status of the field.

Place, publisher, year, edition, pages
Elsevier, 2022
National Category
Biochemistry and Molecular Biology
Identifiers
urn:nbn:se:uu:diva-496774 (URN)10.1016/j.copbio.2022.102693 (DOI)000911874300013 ()35151979 (PubMedID)
Funder
Swedish Foundation for Strategic Research, ITM17-0014Swedish Research Council, 201704125
Available from: 2023-02-21 Created: 2023-02-21 Last updated: 2023-02-21Bibliographically approved
Sarsenbayeva, A., Marques-Santos, C. M., Thombare, K., Di Nunzio, G., Almby, K. E., Lundqvist, M. H., . . . Pereira, M. J. (2019). Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism. Psychoneuroendocrinology, 110, Article ID 104445.
Open this publication in new window or tab >>Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism
Show others...
2019 (English)In: Psychoneuroendocrinology, ISSN 0306-4530, E-ISSN 1873-3360, Vol. 110, article id 104445Article in journal (Refereed) Published
Abstract [en]

Objective: Metabolic syndrome is prevalent in up to 50% of schizophrenia patients, which reduces their quality of life and their compliance with the treatment. It is unclear whether metabolic adverse effects of these agents are due to their direct effect on insulin-sensitive tissues or are secondary to increased adiposity. The study aimed to investigate the direct effects of the second-generation antipsychotics olanzapine and aripiprazole on human subcutaneous adipose tissue and isolated adipocyte metabolism.

Methods: Abdominal subcutaneous adipose tissue needle biopsies were taken from 72 healthy subjects (49 F/23 M; age: 19-78 yr; BMI: 20.0-35.6 kg/m(2)). Isolated adipocytes or adipose tissue were respectively pre-incubated short- (30 min) and long-term (24 h, 72 h) with or without olanzapine (0.004 mu M - 20 mu M) and aripiprazole (0.002 mu M - 100 mu M). Pre-incubated adipose tissue was then snap-frozen for mRNA expression analysis of adipokines genes and genes involved in inflammation, adipogenesis, and mitochondrial function. Isolated adipocytes were used to measure basal and insulin-stimulated glucose uptake and lipolysis.

Results: Acute treatment with a therapeutic concentration of olanzapine decreases basal lipolysis in isolated adipocytes; this effect was not observed after long-term incubation with the drug. Supra-therapeutic concentration of aripiprazole reduced basal and insulin-stimulated glucose uptake after short- and long-term preincubation. Both drugs at supra-therapeutic concentrations downregulated the expression of the pro-inflammatory cytokines IL6 and IL1B genes after 72 h incubation. Similarly, supra-therapeutic concentrations of both drugs and therapeutic concentration of olanzapine, reduced the expression of PPARGC1A, PDK4, and CPT1B genes involved in the regulation of mitochondria] functions. Neither of the antipsychotics affected the expression of the main adipokines LEP and ADIPOQ, genes involved in the regulation of lipid metabolism, LPL and FASN, nor the master adipogenesis regulator, PPARG.

Conclusion: Therapheutic concentrations of olanzapine and aripiprazole have a moderate direct effect on adipocyte lipid and glucose metabolism, respectively. At supra-therapeutic concentrations, both of the antipsychotics seem to act as anti-inflammatory agents and mildly suppressed genes involved in the regulation of mitochondrial functions, which could potentially contribute to metabolic adverse effects. Alternatively, second-generation antipsychotics could induce metabolic side effects via acting on other insulin-sensitive tissues and central nervous system.

Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD, 2019
Keywords
Second-generation antipsychotics, Adipose tissue, Glucose metabolism, Lipid metabolism, Mitochondrial dysfunction, Inflammation
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-400415 (URN)10.1016/j.psyneuen.2019.104445 (DOI)000500388600024 ()31563732 (PubMedID)
Funder
Swedish Society for Medical Research (SSMF)Swedish Diabetes AssociationEXODIAB - Excellence of Diabetes Research in Sweden
Available from: 2020-01-02 Created: 2020-01-02 Last updated: 2021-08-23Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-8433-1725

Search in DiVA

Show all publications